Euro-Excellence Inc v Kraft Canada Inc

Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base

Retrieved on: 
Monday, August 30, 2021
CSE, Program, Research, Health, Lists of diseases, Public health, Safety, OTC, Solution, Rapids, Psilocybin, Suicide, Disorder, Esketamine, Software, American Journal, Ta' Braxia Cemetery, TRD, Forward-looking statement, Risk, Psychiatry, Disclosure, SEDAR, Nursing, CEO, Brain, Industry, The American Journal of Psychiatry, Completeness, Electroconvulsive therapy, IV, Person, Guideline, Randomized controlled trial, Removal of cannabis from Schedule I of the Controlled Substances Act, Depression, Controlled Drugs and Substances Act, Health Canada, Education, Mission statement, Company, Drug prohibition law, FWB, Science, CDSA, Physician, Psychotherapy, System, Marketing, Multimedia, News, Patient, Euro-Excellence Inc v Kraft Canada Inc, Medical device, Pharmaceutical industry, Risk management, Medicine, Audit

"In addition to our clinics, we are executing on our strategy to test out innovative formulations and delivery methods.

Key Points: 
  • "In addition to our clinics, we are executing on our strategy to test out innovative formulations and delivery methods.
  • Increasing Patient Volume:Braxia Scientific, through its four multidisciplinary, community-based Canadian clinics, operating as Braxia Health, continued to see increased patient volume, exceeding its IV ketamine infusion targets every month since January 2021.
  • The Company is confident that the study will demonstrate that the Company can effectively conduct a randomized controlled trial using psychedelic-assisted therapy.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression

Retrieved on: 
Friday, August 27, 2021
Company, Population, Ketamine, CSE, Program, FWB, United States Public Health Service, Electroconvulsive therapy, TRD, Research, Psychotherapy, Person, Randomized controlled trial, Lists of diseases, Health, OTC, Patient, Depression, Rapids, Psilocybin, Euro-Excellence Inc v Kraft Canada Inc, RCT, Disorder, Pharmaceutical industry

Braxia Scientific CEO Dr. Roger McIntyre added, "Integrating psilocybin provides immense opportunity for benefit for those dealing with treatment-resistant depression.

Key Points: 
  • Braxia Scientific CEO Dr. Roger McIntyre added, "Integrating psilocybin provides immense opportunity for benefit for those dealing with treatment-resistant depression.
  • The study will demonstrate that the Company can effectively conduct a randomized controlled trial using psychedelic-assisted therapy.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located inMississauga,Toronto,Ottawa, andMontreal.

Braxia Scientific Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Retrieved on: 
Tuesday, August 17, 2021
Company, Ketamine, CSE, Lists of diseases, Drug prohibition law, FWB, CDSA, Person, Forward-looking statement, Risk, Multimedia, Removal of cannabis from Schedule I of the Controlled Substances Act, OTC, News, Depression, Controlled Drugs and Substances Act, Health Canada, Rapids, Conference, Psilocybin, Euro-Excellence Inc v Kraft Canada Inc, Disorder, Pharmaceutical industry, Audit

TORONTO, Aug. 17, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its management's participation at the upcoming H.C. Wainwright 23rd Annual Global Investment Conference.

Key Points: 
  • TORONTO, Aug. 17, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its management's participation at the upcoming H.C. Wainwright 23rd Annual Global Investment Conference.
  • The conference will be held virtually on September 13-15, 2021.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.

Braxia Scientific Announces Participation at Canaccord Genuity 2021 Annual Growth Conference August 10-12

Retrieved on: 
Friday, August 6, 2021
Health Canada, Company, Psilocybin, Removal of cannabis from Schedule I of the Controlled Substances Act, Disorder, OTC, CSE, Ketamine, Risk, Lists of diseases, FWB, Ta' Braxia Cemetery, Controlled Drugs and Substances Act, Depression, Conference, Person, Multimedia, Rapids, Health, Canaccord Genuity, News, Therapy, CDSA, Drug prohibition law, Forward-looking statement, Euro-Excellence Inc v Kraft Canada Inc, Pharmaceutical industry, Audit

TORONTO, Aug. 6, 2021 /PRNewswire/ -Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference.

Key Points: 
  • TORONTO, Aug. 6, 2021 /PRNewswire/ -Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference.
  • The conference will be held virtually on August 10-12, 2021.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.